Yanbing Ma

Yanbing Ma

Auto-generated profile, based on publicly available information

Yanbing Ma

Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
WHWeiwei Huang
Weiwei Huang
QZQishu Zhang
Qishu Zhang
WLWeiran Li
Weiran Li
MYMingcui Yuan
Mingcui Yuan
JZJingxian Zhou
Jingxian Zhou
YMYanbing Ma
Yanbing Ma

16 November 2016 in Scientific Reports
Verified
Journal Article
Open access
WHWeiwei Huang
Weiwei Huang
SWShijie Wang
Shijie Wang
YYYufeng Yao
Yufeng Yao
YXYe Xia
Ye Xia
XYXu Yang
Xu Yang
YMYanbing Ma
Yanbing Ma
Outer membrane vesicles (OMVs) have proven to be highly immunogenic and induced an immune response against bacterial infection in human clinics and animal models. We sought to investigate whether engineered OMVs can be a feasible antigen-delivery platform for efficiently inducing specific antibody responses. In this study, Omp22 (an outer membrane protein of A. baumannii) was displayed on E. coli DH5α-derived OMVs (Omp22-OMVs) using recombinant gene technology. The morphological features of Omp22-OMVs were similar to those of wild-type OMVs (wtOMVs). Immunization with Omp22-OMVs induced high titers of Omp22-specific antibodies. In a murine sepsis model, Omp22-OMV immunization significantly protected mice from lethal challenge with a clinically isolated A. baumannii strain, which was evidenced by the increased survival rate of the mice, the reduced bacterial burdens in the lung, spleen, liver, kidney, and blood, and the suppressed serum levels of inflammatory cytokines. In vitro opsonophagocytosis assays showed that antiserum collected from Omp22-OMV-immunized mice had bactericidal activity against clinical isolates, which was partly specific antibody-dependent. These results strongly indicated that engineered OMVs could display a whole heterologous protein (~22 kDa) on the surface and effectively induce specific antibody responses, and thus OMVs have the potential to be a feasible vaccine platform.

8 February 2016 in Scientific Reports
Verified
Journal Article
Open access
WHWeiwei Huang
Weiwei Huang
YYYufeng Yao
Yufeng Yao
SWShijie Wang
Shijie Wang
YXYe Xia
Ye Xia
XYXu Yang
Xu Yang
YMYanbing Ma
Yanbing Ma
A. baumannii infections are becoming more and more serious health issues with rapid emerging of multidrug and extremely drug resistant strains, and therefore, there is an urgent need for the development of nonantibiotic-based intervention strategies. This study aimed at identifying whether an outer membrane protein with molecular weight of about 22 kDa (Omp22) holds the potentials to be an efficient vaccine candidate and combat A. baumannii infection. Omp22 which has a molecule length of 217 amino acids kept more than 95% conservation in totally 851 reported A. baumannii strains. Recombinant Omp22 efficiently elicited high titers of specific IgG in mice. Both active and passive immunizations of Omp22 increased the survival rates of mice, suppressed the bacterial burdens in the organs and peripheral blood, and reduced the levels of serum inflammatory cytokines and chemokines. Opsonophagocytosis assays showed in vitro that Omp22 antiserum had highly efficient bactericidal activities on clonally distinct clinical A. baumannii isolates, which were partly complements-dependent and opsonophagocytic killing effects. Additionally, administration with as high as 500 μg of Omp22 didn’t cause obvious pathological changes in mice. In conclusion, Omp22 is a novel conserved and probably safe antigen for developing effective vaccines or antisera to control A. baumannii infections.

1 May 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
WHWeiwei Huang
Weiwei Huang
CSCongyan Shu
Congyan Shu
LHLiangqun Hua
Liangqun Hua
YZYilin Zhao
Yilin Zhao
HXHanghang Xie
Hanghang Xie
YMYanbing Ma
Yanbing Ma

1 September 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SWShijie Wang
Shijie Wang
WHWeiwei Huang
Weiwei Huang
KLKui Li
Kui Li
YYYufeng Yao
Yufeng Yao
XYXu Yang
Xu Yang
YMYanbing Ma
Yanbing Ma
Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor Shijie Wang,1â??3,* Weiwei Huang,1â??3,* Kui Li,1â??3 Yufeng Yao,1â??3 Xu Yang,1â??3 Hongmei Bai,1â??3 Wenjia Sun,1â??3 Cunbao Liu,1â??3 Yanbing Ma1â??3 1Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 2Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, 3Yunnan Engineering Research Center of Vaccine Research and Development on Severe Infectious Diseases, Kunming, Peopleâ??s Republic of China *These authors contributed equally to this work Purpose: Currently, therapeutic tumor vaccines under development generally lack significant effects in human clinical trials. Exploring a powerful antigen delivery system is a potential approach to improve vaccine efficacy. We sought to explore engineered bacterial outer membrane vesicles (OMVs) as a new vaccine carrier for efficiently delivering tumor antigens and provoking robust antitumor immune responses.Materials and methods: First, the tumoral antigen human papillomavirus type 16 early protein E7 (HPV16E7) was presented on Escherichia coli-derived OMVs by genetic engineering methods, acquiring the recombinant OMV vaccine. Second, the ability of recombinant OMVs delivering their components and the model antigen green fluorescent protein to antigen-presenting cells was investigated in the macrophage Raw264.7 cells and in bone marrow-derived dendritic cells in vitro. Third, it was evaluated in TC-1 graft tumor model in mice that the recombinant OMVs displaying HPV16E7 stimulated specific cellular immune response and intervened the growth of established tumor.Results: E. coli DH5α-derived OMVs could be taken up rapidly by dendritic cells, for which vesicle structure has been proven to be important. OMVs significantly stimulated the expression of dendritic cellmaturation markers CD80, CD86, CD83 and CD40. The HPV16E7 was successfully embedded in engineered OMVs through gene recombinant techniques. Subcutaneous immunization with the engineered OMVs induced E7 antigen-specific cellular immune responses, as shown by the increased numbers of interferon-gamma-expressing splenocytes by enzyme-linked immunospot assay and interferon-gamma-expressing CD4+ and CD8+ cells by flow cytometry analyses. Furthermore, the growth of grafted TC-1 tumors in mice was significantly suppressed by therapeutic vaccination. The recombinant E7 proteins presented by OMVs were more potent than those mixed with wild-type OMVs or administered alone for inducing specific cellular immunity and suppressing tumor growth.Conclusion: The results indicated that the nano-grade OMVs might be a useful vaccine platform for antigen delivery in cancer immunotherapy. Keywords: outer membrane vesicles, dendritic cells, HPV immunotherapy

1 August 2015 in Vaccine
Verified
Journal Article
Closed access
WHWeiwei Huang
Weiwei Huang
SWShijie Wang
Shijie Wang
YYYufeng Yao
Yufeng Yao
YXYe Xia
Ye Xia
XYXu Yang
Xu Yang
YMYanbing Ma
Yanbing Ma